Bristol, Pfizer Halt Anti-Clotting Drug Trial on Signal of Benefit - WSJ.com
The drug, apixaban, is designed to prevent clotting of the blood. The New York-based drug makers studied apixaban in people with atrial fibrillation, a disease involving irregular heartbeat that increases the risk for stroke.
1 comment:
Good result. Important to note that the comparator is Aspirin in this study and not Warfarin, which is currently the standard of care in AF
Post a Comment